Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia

Table 4 Prognostic factors of mortality in patients with VAP caused by A. baumannii , univariable Cox’s proportional hazards regression analysis

Predictors	HR	95% CI	P value
Male gender	1.31	0.96–1.79	0.088
Age >60	1.08	0.79–1.48	0.609
Comorbidities
Renal diseases	1.24	0.89–1.70	0.193
Cerebrovascular diseases	0.85	0.59–1.21	0.365
Cardiovascular diseases	0.95	0.67–1.34	0.790
COPD	0.90	0.60–1.37	0.638
DM	1.13	0.76–1.70	0.541
Immunocompromised hosts	1.68	1.18–2.40	0.004
Malignancy	2.24	1.54–3.27	<0.001
Hematologic diseases	1.50	0.92–2.45	0.102
Hepatic diseases	1.15	0.67–2.00	0.601
Late-onset VAP	1.05	0.64–1.71	0.846
CXR: extents of infiltration
Multi-lobes	1.41	0.91–2.19	0.128
Septic shock	6.60	4.54–9.60	<0.001
Severity score
SAPS II >45	5.36	3.71–7.73	<0.001
SOFA >5	8.18	5.20–12.87	<0.001
Admission ≥7 days before VAP onset	1.18	0.85–1.62	0.309
Pathogens
Polymicrobial	1.15	0.84–1.56	0.385
P. aeruginosa	1.34	0.95–1.90	0.095
MRSA	1.45	0.97–2.14	0.065
K. pneumoniae	1.27	0.67–2.41	0.460
Others^a	0.69	0.36–1.30	0.249
Groups of A. baumannii
DS	1
MDR	1.75	0.74–4.16	0.119
XDR	3.38	1.58–7.25	0.002
PDR	4.42	1.60–12.20	0.004
Empirical antibiotic treatment
Combined antibiotics	1.28	0.91–1.78	0.152
Inappropriate	2.30	1.70–3.13	<0.001

SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, DS drug-sensitive, MDR multidrug-resistant, XDR extensively drug-resistant, PDR pandrug-resistant A. baumannii, MRSA methicillin-resistant Staphylococcus aureus, CXR chest X-ray.
^aOthers including E. coli, S. maltophilia, H. influenzae, methicillin-sensitive Staphylococcus aureus, Enterococcus spp., VAP ventilator-associated pneumonia.

ISSN: 2052-0492